ATE493660T1 - Mittel und verfahren zur prognose oder diagnose von diabetes typ ii - Google Patents

Mittel und verfahren zur prognose oder diagnose von diabetes typ ii

Info

Publication number
ATE493660T1
ATE493660T1 AT07727167T AT07727167T ATE493660T1 AT E493660 T1 ATE493660 T1 AT E493660T1 AT 07727167 T AT07727167 T AT 07727167T AT 07727167 T AT07727167 T AT 07727167T AT E493660 T1 ATE493660 T1 AT E493660T1
Authority
AT
Austria
Prior art keywords
prognosis
diabetes
diagnosis
methods
type
Prior art date
Application number
AT07727167T
Other languages
English (en)
Inventor
Bianca Bethan
Kristina Busch
Jan Wiemer
Martijn Gipmans
Edgar Leibold
Jochen Spranger
Thomas Bobbert
Andreas Friedrich Hermann Pfeiffer
Original Assignee
Metanomics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06111705A external-priority patent/EP1837657A1/de
Application filed by Metanomics Gmbh filed Critical Metanomics Gmbh
Application granted granted Critical
Publication of ATE493660T1 publication Critical patent/ATE493660T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]
    • Y10T436/144444—Glucose
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT07727167T 2006-03-24 2007-03-21 Mittel und verfahren zur prognose oder diagnose von diabetes typ ii ATE493660T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06111705A EP1837657A1 (de) 2006-03-24 2006-03-24 Mittel und Verfahren zur Prognose oder Diagnose von Diabetes
EP06120273 2006-09-07
PCT/EP2007/052691 WO2007110357A2 (en) 2006-03-24 2007-03-21 Means and method for diagnosing diabetes

Publications (1)

Publication Number Publication Date
ATE493660T1 true ATE493660T1 (de) 2011-01-15

Family

ID=38016918

Family Applications (2)

Application Number Title Priority Date Filing Date
AT07727167T ATE493660T1 (de) 2006-03-24 2007-03-21 Mittel und verfahren zur prognose oder diagnose von diabetes typ ii
AT07727168T ATE493661T1 (de) 2006-03-24 2007-03-21 Mittel und verfahren zur prognose oder diagnose von diabetes typ ii

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT07727168T ATE493661T1 (de) 2006-03-24 2007-03-21 Mittel und verfahren zur prognose oder diagnose von diabetes typ ii

Country Status (10)

Country Link
US (2) US8216848B2 (de)
EP (6) EP2339346B1 (de)
JP (4) JP5167239B2 (de)
CN (1) CN101438168B (de)
AR (2) AR060120A1 (de)
AT (2) ATE493660T1 (de)
CA (2) CA2647122A1 (de)
DE (2) DE602007011588D1 (de)
ES (4) ES2522815T3 (de)
WO (2) WO2007110358A2 (de)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2339346B1 (de) * 2006-03-24 2014-09-03 Metanomics GmbH Verfahren zur Prognose von Diabetes Typ II
EP2164977B1 (de) 2007-07-17 2013-10-30 Metabolon, Inc. Biomarker für diabetes-vorstufen sowie verfahren zu ihrer verwendung
EP2209001A4 (de) * 2007-10-25 2010-10-27 Ajinomoto Kk Verfahren zur beurteilung von gestörter glucosetoleranz
WO2009153136A2 (en) * 2008-05-28 2009-12-23 Basf Se Means and methods for assessing liver toxicity
US8658427B2 (en) 2008-05-28 2014-02-25 Basf Se Means and methods for assessing increased peroxisomal proliferation
JP2011522231A (ja) * 2008-05-28 2011-07-28 ビーエーエスエフ ソシエタス・ヨーロピア 肝酵素誘導を評価する手段及び方法
CN102119330B (zh) * 2008-07-15 2014-02-12 梅坦诺米克斯保健有限公司 诊断胃改道手术及其相关状况的工具和方法
DE102009013914B4 (de) * 2009-03-19 2011-05-05 Bruker Daltonik Gmbh Kalibriersubstanzen für Atmosphärendruck-Ionenquellen
US20120108668A1 (en) 2009-03-24 2012-05-03 Lundstedt Erik Torbjoern Metabolic profiles
EP2804001B1 (de) * 2009-06-04 2017-08-09 Metanomics Health GmbH Verfahren zur Diagnose von Prostatakarzinomen
US20120132797A1 (en) * 2009-08-13 2012-05-31 Basf Se Means and methods for diagnosing thyroid disorders
US8367359B1 (en) * 2009-10-23 2013-02-05 The United States Of America, As Represented By The Secretary Of Agriculture Metabolic biomarkers for diabetes and insulin resistance
ES2728120T3 (es) * 2010-01-29 2019-10-22 Metanomics Gmbh Medios y procedimientos para diagnosticar insuficiencia cardíaca en un sujeto
US20130126725A1 (en) * 2010-07-30 2013-05-23 Technische Universität Graz Analyses of Analytes by Mass Spectrometry with Values in at Least 3 Dimensions
WO2012051463A2 (en) * 2010-10-14 2012-04-19 The Regents Of The University Of California Urine metabolomic profile of diabetic kidney disease
US20130295692A1 (en) * 2010-12-23 2013-11-07 Metanomics Health Gmbh Means and methods for predicting diabetes
US20130101984A1 (en) * 2011-10-20 2013-04-25 The Washington University Methods of detecting sleepiness
US20150044702A1 (en) * 2012-03-09 2015-02-12 Basf Se Means and methods for assessing disorders related to impaired iron adsorption or energy metabolism
US9928345B2 (en) 2012-06-08 2018-03-27 Liposciences, Inc. Multiple-marker risk parameters predictive of conversion to diabetes
US9470771B2 (en) 2012-06-08 2016-10-18 Liposcience, Inc. NMR measurements of NMR biomarker GlycA
US9361429B2 (en) 2012-06-08 2016-06-07 Liposcience, Inc. Multi-parameter diabetes risk evaluations
EP2867669B1 (de) 2012-06-27 2016-12-21 Metanomics Health GmbH Verfahren zur Identifizierung von Diabetes-Arzneimitteln
WO2014060486A1 (en) 2012-10-18 2014-04-24 Metanomics Gmbh Means and methods for determining a clearance normalized amount of a metabolite disease biomarker in a sample
ES2669620T3 (es) * 2013-01-31 2018-05-28 Metabolon, Inc. Biomarcadores relacionados con el avance de la resistencia a la insulina y métodos que lo utilizan
KR102204498B1 (ko) * 2013-04-09 2021-01-19 아지노모토 가부시키가이샤 생활습관병 지표의 평가 방법, 생활습관병 지표 평가 장치, 생활습관병 지표 평가 방법, 생활습관병 지표 평가 프로그램 제품, 생활습관병 지표 평가 시스템, 및 정보통신 단말장치
CN103616465A (zh) * 2013-10-28 2014-03-05 浙江大学 血液相关脂肪酸谱的建立方法
US20150323520A1 (en) * 2014-05-07 2015-11-12 The Trustees Of The Stevens Institute Of Technology Diagnosis of kidney transplant acute rejection
JP6773951B2 (ja) * 2014-05-30 2020-10-21 学校法人東京医科大学 唾液試料の調製方法
US11255866B2 (en) * 2015-02-26 2022-02-22 Wisconsin Alumni Research Foundation Methods for predicting glucoregulatory dysfunction via diacylglycerol fatty acid species concentrations
KR20170002318A (ko) * 2015-06-29 2017-01-06 고려대학교 산학협력단 대사체 분석을 이용한 당뇨병 조기 진단용 조성물
CN106979982B (zh) * 2016-01-19 2021-01-05 上海市第六人民医院 一种用于糖尿病风险预测、治疗评价的方法及试剂盒
CN105699663A (zh) * 2016-04-06 2016-06-22 深圳市老年医学研究所 2型糖尿病唾液蛋白指纹图谱分子诊断模型建立方法
CN105784829A (zh) * 2016-04-06 2016-07-20 深圳市老年医学研究所 2型糖尿病肾虚证唾液蛋白指纹图谱分子诊断模型建立方法
CN109154619A (zh) * 2016-05-17 2019-01-04 国立大学法人大阪大学 用于判定糖尿病的血液试样的分析方法及系统
US20200033360A1 (en) * 2017-03-31 2020-01-30 Metabolon, Inc. Comprehensive and quantitative lipid and tocopherol analysis
EP3901631A3 (de) * 2017-08-17 2021-12-29 Société des Produits Nestlé S.A. Marker in der vorpubertät für kinder-prädiabetes
CN108362804B (zh) * 2018-02-27 2019-01-29 山东英盛生物技术有限公司 一种检测血液样品中dha含量的方法及试剂盒
CN109507337B (zh) * 2018-12-29 2022-02-22 上海交通大学医学院附属新华医院 一种基于血尿中代谢产物预测甘地胶囊治疗糖尿病肾病机制的新方法
CN111443143B (zh) * 2020-04-30 2022-04-29 宁波市产品食品质量检验研究院(宁波市纤维检验所) 一种快速测定乳粉中胆固醇含量的方法
CN114216851A (zh) * 2020-11-27 2022-03-22 四川大学华西医院 一种基于表面增强拉曼光谱技术的急性胰腺炎评估装置
KR102583808B1 (ko) * 2021-03-05 2023-09-26 경희대학교 산학협력단 눈물을 이용한 당뇨병의 진단 방법 및 키트
CN114324662B (zh) * 2021-12-30 2022-09-16 中南大学 用于诊断或预防糖尿病的血清生物标志物的应用
CN114965753A (zh) * 2022-05-13 2022-08-30 重庆医科大学附属第一医院 一种lgals3bp蛋白丰度检测试剂在制备妊娠期糖尿病泪液诊断试剂中的应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4540884A (en) 1982-12-29 1985-09-10 Finnigan Corporation Method of mass analyzing a sample by use of a quadrupole ion trap
AU590883B2 (en) 1985-05-28 1989-11-23 Nippon Kayaku Kabushiki Kaisha Method of quantitative assay for 1,5-anhydroglucitol
JP2540349B2 (ja) * 1988-01-18 1996-10-02 日本化薬株式会社 腎性糖尿検査方法
US5194448A (en) 1989-11-30 1993-03-16 Croda International Plc Use of nervonic acid and long chain fatty acids for the treatment of demyelinating disorders
DE4242794A1 (en) 1991-12-18 1993-06-24 Nitto Boseki Co Ltd Quantitative automated determn. of 1,5-anhydro:glucitol - using pyranose oxidase from Basidiomycetes fungi no.52
US5624804A (en) * 1991-12-20 1997-04-29 The Rockefeller University Immunochemical detection of In vivo advanced glycosylation end products
US5397894A (en) 1993-05-28 1995-03-14 Varian Associates, Inc. Method of high mass resolution scanning of an ion trap mass spectrometer
JPH0870893A (ja) * 1994-09-02 1996-03-19 Nippon Kayaku Co Ltd 犬の糖尿病診断法、１，５−アンヒドログルシトールの定量法及びキット
JP3579549B2 (ja) * 1995-10-24 2004-10-20 株式会社トクヤマ 糖尿病または糖尿病合併症用マーカーとしての使用
NZ328976A (en) * 1996-02-20 1999-06-29 Kyowa Hakko Kogyo Kk Quantitative determination of 1,5-anhydroglucitol using an enzyme (typically trehalase)
US5965449A (en) 1996-07-03 1999-10-12 Forbes Medi-Tech, Inc. Method of assessing risk for cardiovascular disease and other disorders and phytosterol-based compositions useful in preventing and treating cardiovascular disease and other disorders
US5871949A (en) 1996-12-04 1999-02-16 Daiichi Pure Chemicals Co., Ltd. Method of quantitative assay for 1,5-anhydroglucitol and reagent for quantitative assay
JP3129250B2 (ja) * 1997-09-10 2001-01-29 株式会社ミルス生命科学研究所 尿の化学分析方法
CA2291912A1 (en) 1998-12-11 2000-06-11 Kyowa Medex Co., Ltd. Method and reagent for quantitative determination of 1,5-anhydroglucitol
JP4585693B2 (ja) * 1999-04-22 2010-11-24 リポサイエンス、インコーポレイテッド Ｉｉ型糖尿病を発現する危険性のｎｍｒによる決定方法
US6140067A (en) * 1999-04-30 2000-10-31 Mitokor Indicators of altered mitochondrial function in predictive methods for determining risk of type 2 diabetes mellitus
JP2001330599A (ja) * 2000-05-24 2001-11-30 Shimazu S D Kk Ｇｃ／ｍｓによる代謝異常スクリーニング診断装置
US20020068310A1 (en) 2000-10-11 2002-06-06 Mihoko Sasaki Method and reagant for quantitative determination of 1,5-anhydroglucitol
ES2173049B1 (es) * 2001-03-28 2004-01-16 Oleoyl Estrone Developments S Monoester de acido graso y estrogeno como agente antidiabetico e hipolipemiante.
AU2002320316A1 (en) * 2001-07-06 2003-01-21 Lipomics Technologies, Inc. Generating, viewing, interpreting, and utilizing a quantitative database of metabolites
US7402418B2 (en) * 2001-09-20 2008-07-22 Plantech Research Institute Genes participating in the synthesis of fatty acid having trans-11-,cis-13-conjugated double bond and utilization thereof
CA2459508A1 (en) * 2001-09-24 2003-04-03 Lipomics Technologies, Inc. Methods of using quantitative lipid metabolome data
US7196323B2 (en) 2002-02-28 2007-03-27 Metanomics Gmbh & Co. Kgaa Mass spectrometry method for analyzing mixtures of substances
EP1490076A4 (de) * 2002-03-11 2010-01-06 Lipomics Technologies Inc Neue metabolische targets und marker
US20040132819A1 (en) * 2002-08-06 2004-07-08 Nancy Auestad Appetite control method
JP2004097134A (ja) * 2002-09-11 2004-04-02 Univ Hiroshima 鎖長延長酵素による長鎖脂肪酸の合成法
JP2007523849A (ja) * 2003-05-31 2007-08-23 フォーブス メディ−テック インコーポレーテッド １種以上のフィトステロール及び／又はフィトスタノール、及びグルコマンナンを含む組成物、及びｉｉ型糖尿病を有する又は有さない個体の脂質疾患の治療における該組成物の使用。
WO2005094200A2 (en) * 2003-06-20 2005-10-13 University Of Florida Biomarkers for differentiating between type 2 and type 2 diabetes
JP4066259B2 (ja) * 2003-09-11 2008-03-26 財団法人大阪産業振興機構 軟体動物由来廃棄物の処理方法
CA2556281C (en) * 2004-02-17 2014-09-09 Edward Kane Network and methods for integrating individualized clinical test results and nutritional treatment
US20050202521A1 (en) * 2004-03-10 2005-09-15 Albert Crum Methods of assessing the need for and the effectiveness of therapy with antioxidants
DE602005022704D1 (de) * 2004-06-09 2010-09-16 Dickinson And Co Sensor für mehrere analyte
CN101035594B (zh) * 2004-08-09 2013-10-23 酶学技术有限公司 用于糖尿病患者的食品
JPWO2006073195A1 (ja) * 2005-01-07 2008-06-12 敏一 吉川 糖尿病の予知・診断方法および糖尿病予知・診断用キット
EP2339346B1 (de) 2006-03-24 2014-09-03 Metanomics GmbH Verfahren zur Prognose von Diabetes Typ II
EP2164977B1 (de) * 2007-07-17 2013-10-30 Metabolon, Inc. Biomarker für diabetes-vorstufen sowie verfahren zu ihrer verwendung

Also Published As

Publication number Publication date
WO2007110357A3 (en) 2007-11-15
EP2339346A2 (de) 2011-06-29
JP2013076703A (ja) 2013-04-25
DE602007011592D1 (de) 2011-02-10
EP2008108B1 (de) 2010-12-29
AR060120A1 (es) 2008-05-28
CN101438168A (zh) 2009-05-20
ES2522815T3 (es) 2014-11-18
EP2339346B1 (de) 2014-09-03
EP2336782A1 (de) 2011-06-22
JP2009530626A (ja) 2009-08-27
EP2008108A2 (de) 2008-12-31
EP2369346A3 (de) 2011-11-02
ES2522818T3 (es) 2014-11-18
ES2522816T3 (es) 2014-11-18
JP2013057672A (ja) 2013-03-28
EP2330423A1 (de) 2011-06-08
US20100163720A1 (en) 2010-07-01
US8216848B2 (en) 2012-07-10
ES2525345T3 (es) 2014-12-22
EP2369346B1 (de) 2014-08-27
WO2007110358A3 (en) 2007-11-15
EP2336782B1 (de) 2014-08-27
JP5167239B2 (ja) 2013-03-21
WO2007110358A2 (en) 2007-10-04
JP5579819B2 (ja) 2014-08-27
CA2647122A1 (en) 2007-10-04
DE602007011588D1 (de) 2011-02-10
JP2009530627A (ja) 2009-08-27
EP2005189A2 (de) 2008-12-24
EP2330423B1 (de) 2014-10-01
AR060121A1 (es) 2008-05-28
JP5199994B2 (ja) 2013-05-15
ATE493661T1 (de) 2011-01-15
US8216847B2 (en) 2012-07-10
CA2647197A1 (en) 2007-10-04
US20100236321A1 (en) 2010-09-23
EP2339346A3 (de) 2011-10-19
EP2005189B1 (de) 2010-12-29
CN101438168B (zh) 2013-10-16
WO2007110357A2 (en) 2007-10-04
EP2369346A2 (de) 2011-09-28

Similar Documents

Publication Publication Date Title
ATE493660T1 (de) Mittel und verfahren zur prognose oder diagnose von diabetes typ ii
BRPI0914801A2 (pt) método para detectar o grupo sanguíneo abo/rh/mn humano, e, kit
ATE500824T1 (de) Verfahren zur reinigung von trans-(-)-delta9- tetrahydrocannabinol und trans-(+)-delta9- tetrahydrocannabinol
DE602005024639D1 (de) Verfahren und Gerät zur Diagnose des Ermüdungsversagens von Turboladern
DE602006020741D1 (de) Strommessschaltung und verfahren zur fehlerdiagnose darin
ATE530558T1 (de) Verfahren und verbindungen zur herstellung von natriumglucose-co-transporter-2-hemmern
DE112006000054A5 (de) Verfahren zur Diagnose eines Abgasnachbehandlungssystems
DE112005002742A5 (de) Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreasererkrankungen
DE602007008174D1 (de) Verfahren und System zur Erkennung von Phishing
DE502007006027D1 (de) Abgasnachbehandlungssystem und verfahren zur abgasreinigung
DE602007005817D1 (de) System zur überwachung des katalysatorverschleisses und verfahren zur überwachung des katalysatorverschleisses
ATE437580T1 (de) Mehrkomponentes filter zur mehreren geschmacksverstärkung
AT502349A3 (de) Verfahren zur auswertung von touch-signalen und touch-einheit
ATE433675T1 (de) Neue zusammensetzung zur verbesserung des hautzustandes und verfahren zu ihrer herstellung
DE602007005069D1 (de) Verfahren und/oder Systeme zur Beleuchtung von Strichcodes
DE602005007317D1 (de) Verfahren und System für Ultraschalluntersuchung
BRPI0906094A2 (pt) composto e método de tratamento de diabetes do tipo ii
ATE479100T1 (de) Verfahren zur diagnose von lawsonia intracellularis
DE112009001253A5 (de) Verfahren und Kit zur Dotierung oder Einfärbung von porösen Keramiken
BRPI1015014A2 (pt) composto, composição farmacêutica , e, método de tratamento de distúrbio(s) cognitivo(s) ou indicações com déficit(s) em cognição
DE602006021612D1 (de) Systeme und verfahren zur messung von glykiertem hämoglobin
DE602006014106D1 (de) Verfahren zur diagnose von prostatakrebs
DE602007009541D1 (de) System und verfahren zur katalysatorüberwachung
ITVI20050059A1 (it) Nuovi biomarcatori per la diagnosi e/o la prognosi di neoplasie in animali
DE102008009718A8 (de) Verfahren und Mittel zur Enkodierung von Hintergrundrauschinformationen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2005189

Country of ref document: EP